Payment overview · 2025
General Payments
$999.27
56 reported records · 15 companies
Healthcare provider profile · identity verified
Matthew J Fackrell, DO
Allopathic & Osteopathic Physicians|Family Medicine · BLACKFOOT, ID · NPI 1215968045
Verified facts
What the public records show
CMS Open Payments records show Matthew J Fackrell, DO received $999.27 in general payments during 2025 across 56 reported records.
ABBVIE INC. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $221.88 | 22.2% | 18 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $200.65 | 20.1% | 11 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $159.23 | 15.9% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $70.28 | 7.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.23 | 6.8% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.47 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.16 | 4.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.42 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.33 | 3.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.38 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.57 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.52 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.84 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.95 | 1.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.36 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $999.27 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $200.65 | 11 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $159.23 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.52 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.36 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.84 | 5 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $70.28 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $68.23 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.47 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.33 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $4.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 584 | 151 |
| Omeprazole | Omeprazole | 402 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 105 |
| Losartan Potassium | Losartan Potassium | 293 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 84 |
| Lisinopril | Lisinopril | 288 | 88 |
| Metformin Hcl Er | Metformin Hcl | 262 | 68 |
| Gabapentin | Gabapentin | 240 | 67 |
| Carvedilol | Carvedilol | 219 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 69 |
| Trazodone Hcl | Trazodone Hcl | 206 | 53 |
| Celecoxib | Celecoxib | 203 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 72 |
| Ozempic | Semaglutide | 171 | 28 |
| Metformin Hcl | Metformin Hcl | 166 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 152 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 80 |
| Montelukast Sodium | Montelukast Sodium | 134 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 29 |
| Potassium Chloride | Potassium Chloride | 123 | 42 |
| Furosemide | Furosemide | 117 | 46 |
| Doxycycline Hyclate | Doxycycline Hyclate | 113 | 86 |
| Mounjaro | Tirzepatide | 113 | 17 |
| Sertraline Hcl | Sertraline Hcl | 113 | 33 |
| Tramadol Hcl | Tramadol Hcl | 111 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 80 |
| Eliquis | Apixaban | 93 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 21 |
| Bupropion Xl | Bupropion Hcl | 83 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 24 |
| Simvastatin | Simvastatin | 79 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 19 |
| Alendronate Sodium | Alendronate Sodium | 75 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 24 |
| Trulicity | Dulaglutide | 68 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 20 |
| Meloxicam | Meloxicam | 66 | 20 |
| Prednisone | Prednisone | 65 | 35 |
| Finasteride | Finasteride | 62 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 14 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 12 |
| Cephalexin | Cephalexin | 52 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 18 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 50 | 13 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 42 |
| Allopurinol | Allopurinol | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 14 |
| Breyna | Budesonide/Formoterol Fumarate | 39 | 13 |
| Estradiol | Estradiol | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 23 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 28 |
| Buspirone Hcl | Buspirone Hcl | 34 | 11 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 25 |
| Clotrimazole | Clotrimazole | 30 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 27 | 12 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | 13 |
| Linzess | Linaclotide | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 15 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ramipril | Ramipril | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $999.27 · 56 records | ABBVIE INC. | ARISTADA, Auvelity, CAPLYTA, FANAPT, GEMTESA, LEQVIO, LYBALVI, NURTEC ODT, Omnipod, QULIPTA, REXULTI, SPRAVATO, SYNTHROID, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error